Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study

• Published in: The Lancet infectious diseases 2017-01, Vol.17 (1), p.68-77
• Main Authors: Chow, Eric P F, Dr, Machalek, Dorothy A, PhD, Tabrizi, Sepehr N, Prof, Danielewski, Jennifer A, PhD, Fehler, Glenda, MSc, Bradshaw, Catriona S, PhD, Garland, Suzanne M, Prof, Chen, Marcus Y, PhD, Fairley, Christopher K, Prof
• Format: Article
• Language: English
• Subjects: Adolescent; Australia - epidemiology; Chlamydia trachomatis; Female; Females; Genotype; Genotypes; Human papillomavirus; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - administration & dosage; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology; Humans; Immunization Programs; Infectious Disease; Infectious diseases; Male; Medical research; Observational studies; Papillomaviridae; Papillomaviridae - chemistry; Papillomaviridae - classification; Papillomaviridae - immunology; Papillomaviridae - isolation & purification; Papillomavirus Infections - epidemiology; Papillomavirus Infections - prevention & control; Papillomavirus Infections - virology; Prevalence; Reproductive Health; Retrospective Studies; Sexual health; Vaccination - utilization; Vaccines; Warts; Young Adult; Young adults
• ISSN: 1473-3099; 1474-4457
• DOI: 10.1016/S1473-3099(16)30116-5

Summary Background Australia introduced a national quadrivalent human papillomavirus (4vHPV) vaccination programme for girls and young women in April, 2007. The HPV genotypes targeted by the female vaccine could also affect the protection afforded to heterosexual men. We examined the prevalence of 4vHPV targeted vaccine genotypes and the nine-valent HPV (9vHPV)-targeted vaccines genotypes among sexually active, predominantly unvaccinated heterosexual men from 2004 to 2015. Methods We did a retrospective, observational study of urine and urethral swab specimens from heterosexual men aged 25 years or younger attending the Melbourne Sexual Health Centre between July 1, 2004, and June 30, 2015, who tested positive for Chlamydia trachomatis . We extracted HPV DNA and used the PapType HPV assay to detect 14 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and two low-risk genotypes (6 and 11). We calculated the prevalence of any HPV genotype, genotypes 6 or 11, genotypes 16 or 18, genotypes in the 4vHPV group (6, 11, 16, or 18), five additional genotypes in the 9vHPV group (31, 33, 45, 52, or 58), and non-vaccine-targeted genotypes (31, 33, 35, 39, 45, 51, 56, 58, 59, 66, or 68). Findings We obtained data between July 1, 2004, and June 30, 2015, and did the data analysis in December, 2015. Of 1764 specimens obtained, we included 1466 in our final analysis (the others were excluded because they had indeterminate results or were duplicates). The prevalence of any HPV genotype and genotypes 31, 33, 45, 52, and 58 did not change from 2004–05 to 2014–15, but we noted reductions in genotypes 6 and 11 (from 12% [95% CI 6–21%], to 3% [1–7%], ptrend =0·008), 16 and 18 (from 13% [95% CI 7–22%] to 3% [1–6%], ptrend